Skip to the page content
Your donations
Passes our checks

Wisconsin Institute for Immune and Cell Therapy Inc

EIN 87-1500208 · Madison, WI

Public records show a registered, tax-exempt organization in good standing.

LegitimacyPassesRegistration and standingFinancial healthStrong100 out of 100GovernanceFair61 out of 100Impact evidenceDescribes programsHow well its results are evidenced

What it says it does

THE ORGANIZATION'S PRIMARY EXEMPT PURPOSE IS TO ENGAGE IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH A HOSPITAL.

Income
$2.1 million
Spending
$404,954
Spent on programs
87%
Reserves
53.6 months of spending
Largest source of income
donations and private grants, 99%
Employees
5
Volunteers
3

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Financial health

Strong: 100 out of 100. Higher than 81% of charities in its peer group (medical research, $1m to $10m).

  • Reserves

    35 of 35

    Spendable reserves would cover 53.6 months of spending.

  • Debt

    20 of 20

    It owes 1% of what it owns.

  • Living within its means

    15 of 15

    Income exceeded spending by 80% of income.

  • Income trend

    15 of 15

    Income rose 224% on the year before.

  • Spending floor

    15 of 15

    87% of spending went to programs and raising each dollar of donations cost 0 cents.

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Governance

Fair: 61 out of 100. Higher than 13% of charities in its peer group (medical research, $1m to $10m).

  • Independent board

    18 of 25

    3 of 3 voting board members are independent.

  • Conflict of interest policy

    15 of 15

    Has a written conflict of interest policy.

  • Whistleblower policy

    0 of 8

    Reports no written whistleblower policy.

  • Record keeping policy

    0 of 7

    Reports no written policy on keeping and destroying records.

  • Board minutes

    5 of 5

    Keeps minutes of board meetings.

  • Board sees the tax return

    10 of 10

    Gave the board a copy of this return before filing it.

  • Independent check of accounts

    0 of 15

    Its accounts were not audited or reviewed by an independent accountant.

  • No reported misuse

    10 of 10

    Reports no diversion of assets, excess benefits or loans to insiders.

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (1)
  1. $350,818 spent. IN 2024, WIICT CONTINUOUSLY CONDUCTED RESEARCH ON AND PROVIDED 4 DIFFERENT MRNAS TO ITS COLLABORATORS AT NIH CLINICAL CANCER CENTER IN BETHESDA, MD FOR EVALUATION AND USE IN CLINICAL RESEARCH AND IN DIFFERENT PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS. ONE OF THESE MRNAS ENCODES THE ACTIVE FORM OF A PROTEIN THAT IS INACTIVE OR LACKING IN ONE TYPE OF IMMUNE CELL OF PATIENTS HAVING A CERTAIN PRIMARY IMMUNODEFICIENCY (PID) DUE TO A MUTATION IN THE GENE THAT IS REQUIRED TO KILL MICROBIAL OR VIRAL PATHOGENS WITH WHICH THE PATIENT BECOMES INFECTED (ON AVERAGE EVERY 2-3 YRS). THIS TRIAL IS TESTING WHETHER PATIENTS CAN BE TREATED BY TRANSFECTING THE MRNA ENCODING THE ACTIVE PROTEIN INTO DEFECTIVE IMMUNE CELLS FROM THE PATIENT'S OWN BLOOD AND THEN REINTRODUCING THOSE TRANSFECTED CELLS INTO THE PATIENT. IN 2024, WIICT ALSO DESIGNED, MADE AND CONDUCTED RESEARCH ON THE YIELDS, PURITIES, ACTIVITIES, FUNCTIONS AND PROPERTIES OF MULTIPLE DIFFERENT BASE EDITING ENZYMES, GENE EDITING ENZYMES, AND BXB1 RECOMBINASE VARIANTS, WHICH MRNAS WERE PROVIDED TO OUR COLLABORATORS AND NIH, MASS GENERAL HOSPITAL AND ST JUDE'S CHILDREN'S HOSPITAL FOR THEIR EVALUATION AND RESEARCH RE ON- TARGET AND OFF-TARGET EDITING OF DIFFERENT GENES AND MUTATIONS IN HUMAN CELLS OR ANIMAL MODELS TO GENERATE DATA TO SUPPORT INDS FOR PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS, INCLUDING BY USING DIFFERENT GUIDE RNAS AND OTHER CONDITIONS AND PARAMETERS TO ACHIEVE OPTIMAL EDITING OF SPECIFIC GENES AND MUTATIONS. IN 2024, WIICT CONTINUOUSLY CONDUCTED RESEARCH ON AND PROVIDED 4 DIFFERENT MRNAS TO ITS COLLABORATORS AT NIH CLINICAL CANCER CENTER IN BETHESDA, MD FOR EVALUATION AND USE IN CLINICAL RESEARCH AND IN DIFFERENT PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS. ONE OF THESE MRNAS ENCODES THE ACTIVE FORM OF A PROTEIN THAT IS INACTIVE OR LACKING IN ONE TYPE OF IMMUNE CELL OF PATIENTS HAVING A CERTAIN PRIMARY IMMUNODEFICIENCY (PID) DUE TO A MUTATION IN THE GENE THAT IS REQUIRED TO KILL MICROBIAL OR VIRAL PATHOGENS WITH WHICH THE PATIENT BECOMES INFECTED (ON AVERAGE EVERY 2-3 YRS). THIS TRIAL IS TESTING WHETHER PATIENTS CAN BE TREATED BY TRANSFECTING THE MRNA ENCODING THE ACTIVE PROTEIN INTO DEFECTIVE IMMUNE CELLS FROM THE PATIENT'S OWN BLOOD AND THEN REINTRODUCING THOSE TRANSFECTED CELLS INTO THE PATIENT. IN 2024, WIICT ALSO DESIGNED, MADE AND CONDUCTED RESEARCH ON THE YIELDS, PURITIES, ACTIVITIES, FUNCTIONS AND PROPERTIES OF MULTIPLE DIFFERENT BASE EDITING ENZYMES, GENE EDITING ENZYMES, AND BXB1 RECOMBINASE VARIANTS, WHICH MRNAS WERE PROVIDED TO OUR COLLABORATORS AND NIH, MASS GENERAL HOSPITAL AND ST JUDE'S CHILDREN'S HOSPITAL FOR THEIR EVALUATION AND RESEARCH RE ON- TARGET AND OFF-TARGET EDITING OF DIFFERENT GENES AND MUTATIONS IN HUMAN CELLS OR ANIMAL MODELS TO GENERATE DATA TO SUPPORT INDS FOR PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS, INCLUDING BY USING DIFFERENT GUIDE RNAS AND OTHER CONDITIONS AND PARAMETERS TO ACHIEVE OPTIMAL EDITING OF SPECIFIC GENES AND MUTATIONS.

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated October 13, 2026.

  3. Are donations tax-deductible? Passed.

    On the IRS list of organizations eligible to receive tax-deductible contributions.

    Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending December 2025.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since January 2023.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 21, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.